Developer docs
API playgroundTry for free, no card

Search company profiles

Immunic Therapeutics

Full company profile

uuid0002n2q

Namestring
Immunic Therapeutics
Legal namestring
Immunic, Inc.
Websiteurl
imux.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Immunic Therapeutics (NASDAQ: IMUX) is a late-stage clinical biopharmaceutical company developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with a primary focus on multiple sclerosis (MS). Founded in 2016 as Immunic AG in Gräfelfing, Germany, the company reached the public markets in 2019 via a reverse takeover with Vital Therapies and is now headquartered in New York, NY with an Australian operating subsidiary. Immunic employs 51–100 people across its U.S., German and Australian operations.

The company's lead asset is vidofludimus calcium (IMU-838), a small molecule that combines selective dihydroorotate dehydrogenase (DHODH) inhibition with Nurr1 receptor activation, positioning it as a first-in-class oral immunomodulator with both anti-inflammatory and neuroprotective mechanisms. It is being evaluated in two Phase 3 ENSURE trials in relapsing MS (top-line data expected end of 2026) with a planned NDA submission in mid-2027, and management has signalled intent to expand into primary progressive MS (PPMS), a separate underserved segment. The broader pipeline includes IMU-856, a Sirtuin 6 (SIRT6) modulator being explored for celiac disease, and the IMU-381 discovery-stage platform. European patent EP3713554 protects vidofludimus calcium dosing regimens through 2038.

Immunic is pre-revenue and has funded operations entirely through equity financings and a reverse merger, with cumulative net losses of $97.2 million in 2025 and $100.5 million in 2024. A $400 million private placement in February 2026, led by BVF Partners, is intended to fund the company through NDA submission. The commercial model under construction relies on a specialty pharmacy and neurology channel in the U.S., targeting a fragmented prescriber base (neurologists) and an MS patient population of approximately 1 million in the U.S. and roughly 2.8 million globally. The newly appointed CEO Erik Lundgren, CMO Dr. Michael Panzara and Board Chair Michael W. Bonney all bring prior MS franchise commercialization experience, including Ocrevus (Roche), LEMTRADA and AUBAGIO (Genzyme/Sanofi), and Biogen/Cubist, indicating the company is actively building a commercial-stage organization ahead of the anticipated launch window.

Short descriptiontext

Immunic Therapeutics (NASDAQ: IMUX) is a late-stage clinical biopharmaceutical company developing orally administered small molecule therapies for multiple sclerosis and other chronic inflammatory and autoimmune diseases, with lead candidate vidofludimus calcium in Phase 3 trials and a planned NDA submission in mid-2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral small molecule therapeutics, multiple sclerosis treatments, immunology drug development, autoimmune disease therapies, neurodegenerative disease pipeline
Industry3 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue biotechnology company preparing for commercialization of vidofludimus calcium for multiple sclerosis. Planned NDA submission in mid-2027 with potential approval in 2028. Revenue expected from product sales upon regulatory approval.

ir.imux.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Immunic Therapeutics is a late-stage biotechnology company developing orally administered small molecule drug candidates targeting chronic inflammatory, autoimmune, and neurologic diseases. Its lead asset, vidofludimus calcium (IMU-838), is in Phase 3 ENSURE clinical trials for relapsing multiple sclerosis, with additional development planned for primary progressive MS, and combines first-in-class Nurr1 activation with selective DHODH inhibition.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 31% reduction in confirmed disability worsening in primary progressive MS patients (Phase 2 CALLIPER)
+3 more records
Product overview1 text field

Immunic Therapeutics is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and autoimmune diseases. The company's development pipeline consists of three clinical-stage programs: (1) Vidofludimus Calcium (IMU-838) is the lead asset in Phase 3 clinical trials for relapsing multiple sclerosis with additional development planned for primary progressive MS; (2) IMU-856 is a selective Sirtuin 6 modulator targeting celiac disease and gastrointestinal disorders; and (3) IMU-381 represents an earlier-stage program addressing neurodegenerative, chronic inflammatory, and autoimmune diseases. The company is transitioning from an R&D-focused organization toward a commercial-stage company.

Product and service3 records
1Vidofludimus Calcium (IMU-838)
CategoryMultiple Sclerosis Therapeutic
Description

An orally administered investigational small molecule combining neuroprotective effects as a first-in-class Nurr1 activator with anti-inflammatory and anti-viral effects via selective DHODH inhibition. Currently in Phase 3 ENSURE trials for relapsing multiple sclerosis and being evaluated for primary progressive MS.

2IMU-856
CategoryGastrointestinal Disease Therapeutic
Description

A selective Sirtuin 6 (Sirt6) modulator with novel binding characteristics being developed as an oral treatment for celiac disease and other gastrointestinal disorders, aiming to address unmet needs for patients with inflammatory bowel conditions.

3IMU-381
CategoryAutoimmune/Neurodegenerative Therapeutic Platform
Description

An earlier-stage research program intended to build a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors31 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunic Therapeutics

Biopharmaceutical Therapeuticsimux.com

Immunic Therapeutics (NASDAQ: IMUX) is a late-stage clinical biopharmaceutical company developing orally administered small molecule therapies for multiple sclerosis and other chronic inflammatory and autoimmune diseases, with lead candidate vidofludimus calcium in Phase 3 trials and a planned NDA submission in mid-2027.

What Immunic Therapeutics does

Immunic Therapeutics (NASDAQ: IMUX) is a late-stage clinical biopharmaceutical company developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with a primary focus on multiple sclerosis (MS). Founded in 2016 as Immunic AG in Gräfelfing, Germany, the company reached the public markets in 2019 via a reverse takeover with Vital Therapies and is now headquartered in New York, NY with an Australian operating subsidiary. Immunic employs 51–100 people across its U.S., German and Australian operations.

The company's lead asset is vidofludimus calcium (IMU-838), a small molecule that combines selective dihydroorotate dehydrogenase (DHODH) inhibition with Nurr1 receptor activation, positioning it as a first-in-class oral immunomodulator with both anti-inflammatory and neuroprotective mechanisms. It is being evaluated in two Phase 3 ENSURE trials in relapsing MS (top-line data expected end of 2026) with a planned NDA submission in mid-2027, and management has signalled intent to expand into primary progressive MS (PPMS), a separate underserved segment. The broader pipeline includes IMU-856, a Sirtuin 6 (SIRT6) modulator being explored for celiac disease, and the IMU-381 discovery-stage platform. European patent EP3713554 protects vidofludimus calcium dosing regimens through 2038.

Immunic is pre-revenue and has funded operations entirely through equity financings and a reverse merger, with cumulative net losses of $97.2 million in 2025 and $100.5 million in 2024. A $400 million private placement in February 2026, led by BVF Partners, is intended to fund the company through NDA submission. The commercial model under construction relies on a specialty pharmacy and neurology channel in the U.S., targeting a fragmented prescriber base (neurologists) and an MS patient population of approximately 1 million in the U.S. and roughly 2.8 million globally. The newly appointed CEO Erik Lundgren, CMO Dr. Michael Panzara and Board Chair Michael W. Bonney all bring prior MS franchise commercialization experience, including Ocrevus (Roche), LEMTRADA and AUBAGIO (Genzyme/Sanofi), and Biogen/Cubist, indicating the company is actively building a commercial-stage organization ahead of the anticipated launch window.

Immunic Therapeutics firmographics

Firmographics
Name
Immunic Therapeutics
Legal name
Immunic, Inc.
Website
https://imux.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Immunic Therapeutics (NASDAQ: IMUX) is a late-stage clinical biopharmaceutical company developing orally administered small molecule therapies for multiple sclerosis and other chronic inflammatory and autoimmune diseases, with lead candidate vidofludimus calcium in Phase 3 trials and a planned NDA submission in mid-2027.
Ownership category
akta.pro rank

Immunic Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals

Keywords

  • Oral small molecule therapeutics
  • Multiple sclerosis treatments
  • Immunology drug development
  • Autoimmune disease therapies
  • Neurodegenerative disease pipeline

Where Immunic Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Immunic Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue biotechnology company preparing for commercialization of vidofludimus calcium for multiple sclerosis. Planned NDA submission in mid-2027 with potential approval in 2028. Revenue expected from product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Immunic Therapeutics product offering

Product offering

Core offering

Immunic Therapeutics is a late-stage biotechnology company developing orally administered small molecule drug candidates targeting chronic inflammatory, autoimmune, and neurologic diseases. Its lead asset, vidofludimus calcium (IMU-838), is in Phase 3 ENSURE clinical trials for relapsing multiple sclerosis, with additional development planned for primary progressive MS, and combines first-in-class Nurr1 activation with selective DHODH inhibition.

Product overview

Immunic Therapeutics is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and autoimmune diseases. The company's development pipeline consists of three clinical-stage programs: (1) Vidofludimus Calcium (IMU-838) is the lead asset in Phase 3 clinical trials for relapsing multiple sclerosis with additional development planned for primary progressive MS; (2) IMU-856 is a selective Sirtuin 6 modulator targeting celiac disease and gastrointestinal disorders; and (3) IMU-381 represents an earlier-stage program addressing neurodegenerative, chronic inflammatory, and autoimmune diseases. The company is transitioning from an R&D-focused organization toward a commercial-stage company.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vidofludimus Calcium (IMU-838) An orally administered investigational small molecule combining neuroprotective effects as a first-in-class Nurr1 activator with anti-inflammatory and anti-viral effects via selective DHODH inhibition. Currently in Phase 3 ENSURE trials for relapsing multiple sclerosis and being evaluated for primary progressive MS.
  • IMU-856 A selective Sirtuin 6 (Sirt6) modulator with novel binding characteristics being developed as an oral treatment for celiac disease and other gastrointestinal disorders, aiming to address unmet needs for patients with inflammatory bowel conditions.
  • IMU-381 An earlier-stage research program intended to build a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases.

Quantifiable outcome

  • 31% reduction in confirmed disability worsening in primary progressive MS patients (Phase 2 CALLIPER)
  • +3 more outcomes

Companies that use Immunic Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Immunic Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Immunic Therapeutics partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Immunic Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

Immunic Therapeutics social profiles

Digital presence

Immunic Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunic Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Immunic Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Immunic Therapeutics funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors31 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunic Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunic Therapeutics

What does Immunic Therapeutics do?

Immunic Therapeutics is a late-stage biotechnology company developing orally administered small molecule drug candidates targeting chronic inflammatory, autoimmune, and neurologic diseases. Its lead asset, vidofludimus calcium (IMU-838), is in Phase 3 ENSURE clinical trials for relapsing multiple sclerosis, with additional development planned for primary progressive MS, and combines first-in-class Nurr1 activation with selective DHODH inhibition.

Is Immunic Therapeutics a public or private company?

Immunic Therapeutics is a public company. It is classified as public and is currently operating.

When was Immunic Therapeutics founded?

Immunic Therapeutics was founded in 2016. It employs 51 to 100 people.

Where is Immunic Therapeutics based?

Immunic Therapeutics is headquartered in New York, United States, in the North America region.

How does Immunic Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Does Immunic Therapeutics have an API?

No public API is recorded for Immunic Therapeutics.

What industry is Immunic Therapeutics in?

Immunic Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeImmunic Reports $42.3 Million Third-Quarter Loss as ENSURE Data Nears | IMUX Stock NewsImmunic reported a Q3 net loss of $42.3 million, or $0.99 per share, with $132 million in cash expected to support operations into late 2027. Top-line data from Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis are expected in December 2026, with a potential U.S. NDA submission in mid-2027 if results are positive.Business & FinancialImmunic, Inc. Reports Third Quarter 2026 Financial Results And Provides Corporate UpdateImmunic reported Q3 2026 net loss of $42.3 million and cash of $132 million. Its Phase 3 ENSURE trials in relapsing MS are on track for top-line data in December 2026, with a potential NDA submission in mid-2027 if positive.TradingViewImmunic 3Q 2026: EPS ($0.99) — 10-Q SummaryImmunic reported a net loss of $42.3 million for the third quarter of 2026, down from $25.6 million a year earlier, with diluted EPS of -$0.99. Operating expenses rose 67% to $43.4 million, driven by a 225% increase in general and administrative costs. The company expects top-line data from its Phase 3 relapsing MS trials in December 2026.TradingViewImmunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateImmunic reported Q3 2026 net loss of $42.3 million and cash of $132 million. Its Phase 3 ENSURE trials in relapsing MS are on track for top-line data in December 2026, with a potential NDA submission in mid-2027. A Phase 3 trial in progressive MS is ongoing, with first-patient-enrollment expected in the first half of 2027.TradingViewImmunic, Inc. (IMUX) Reports $42.3M Q3 Net Loss; Cash Runway Into Late 2027Immunic reported a Q3 2026 net loss of $42.3M, or $0.99 per share, versus $25.6M a year earlier. Cash of $132.0M is expected to fund operations into late 2027, with top-line data for ENSURE-1 and ENSURE-2 expected in December 2026.PR NewswireImmunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateImmunic reported Q3 2026 net loss of $42.3 million and cash of $132 million. Its Phase 3 ENSURE trials in relapsing MS are on track for December 2026 top-line data, with a potential NDA submission in mid-2027 if positive. The Phase 3 PROTECT-MS trial in progressive MS is ongoing, with first-patient-enrollment expected in the first half of 2027.Investing.comImmunic at Stifel 2026 Healthcare Conference 2026: MS data loomImmunic announced at Stifel 2026 that its two Phase III relapsing MS studies, ENSURE-1 and ENSURE-2, will read out in December, potentially enabling an NDA filing for vidofludimus calcium. The company expects a 30% relapse reduction and is starting a third Phase III study in progressive MS. It also noted a $200 million cash raise and potential warrant proceeds.MarketBeatImmunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 ResultsImmunic plans a Phase 3 trial of vidofludimus calcium for progressive MS, with first patients expected in the first half of 2027. The trial follows a Phase 2 study that missed its primary endpoint but showed exploratory signals on disability measures. The company expects results from two relapsing MS trials in December.TradingViewImmunic to Host Progressive MS Research and Development Day WebinarImmunic will host a webinar on progressive multiple sclerosis research and development on November 5, 2026, from 12:30 to 2:00 p.m. ET via video conference. The company will present a slide deck as Exhibit 99.1 to its 8-K filing, and cautioned that statements about development programs and clinical trials are forward-looking.American Banking and Market NewsImmunic, Inc. (NASDAQ:IMUX) Stock Has Average Target Price of $35.43Immunic's stock has a consensus Buy rating from 14 analysts, with an average 12-month price target of $35.43. The company reported a Q2 loss of $0.80 per share, beating estimates, and 51.82% of shares are held by institutional investors.